tbuckley/cabot-search huggingface dataset:
The lives of cells, recorded
Authors: Amjad Askary, Wei Chen, Junhong Choi, Lucia Y. Du, Michael B. Elowitz, James A. Gagnon, Alexander F. Schier, Sophie Seidel, Jay Shendure, Tanja Stadler, Martin Tran
Journal: Nature Reviews Genetics (2024)

A paradigm for biology is emerging in which cells can be genetically programmed to write their histories into their own genomes. These records can subsequently be read, and the cellular histories reconstructed, which for each cell could include a record of its lineage relationships, extrinsic influences, internal states and physical locations, over time. DNA recording has the potential to transform the way that we study developmental and disease processes. Recent advances in genome engineering are driving the development of systems for DNA recording, and meanwhile single-cell and spatial omics technologies increasingly enable the recovery of the recorded information. Combined with advances in computational and phylogenetic inference algorithms, the DNA recording paradigm is beginning to bear fruit. In this Perspective, we explore the rationale and technical basis of DNA recording, what aspects of cellular biology might be recorded and how, and the types of discovery that we anticipate this paradigm will enable.
About Whom Are We Talking When We Use Intellectual and Developmental Disabilities?
Authors: Marc J. Tassé, Susan M. Havercamp, Gloria Krahn, Karrie A. Shogren, Alexandra Bonardi, Minje Kim, Richard Chapman, Rebecca Andridge, L. Eugene Arnold, Jarrett Barnhill, Shawn Bodle, Ethan Boerner, Mary Lou Bourne, Brian Boyd, Christine Brown, Andrew S. Buck, Sarah Burkett, Mackenzie Burness, Chelsea Cobranchi, Christopher Cole, Daniel K. Davies, Travis Dresbach, Carnicia Eghan, Mary Lee Fay, Robert Fletcher, Ruben Garcia, Braden Gertz, Erin Harris, Jill Hollway, Margo Izzo, Andrew Jahoda, Rosie Lawrence-Slater, Luc Lecavalier, Andrew Lincoln, Ruth Emmanuel Michael, Arielle Mulligan, Alexa J. Murray, Stacy L. Nonnemacher, Mirian E. Ofonedu, Morénike Giwa Onaiwu, Eduardo A. Ortiz, Kristin Page, Samantha Perry, Ashley Poling, Thomas Quade, Paula Rabidoux, Robert Rice, Taylor Richardson, Ann Robinson, Margaret Rosencrans, Megan Ryan, Christopher Sanford, Colin Schaffer, John R. Seeley, Annie Song, Mary Sowers, Kristy Stepp, Marci Straughter, Lara Sucheston-Campbell, Christopher Taylor, Katherine Walton, Kelsi Weaver, Michael Wehmeyer, Craig Williams, Derrick K. Willis, Philip Wilson, Andrea Witwer
Journal: JAMA Pediatrics (2024)

Communicating clearly about who is included in a population group is a critical element to effective dissemination and knowledge transfer. This narrative review highlights the inconsistency as it relates to communicating about individuals with intellectual disability (ID) and developmental disability (DD).
Multilevel Intervention and Outreach for Colorectal Cancer Screening
Authors: Aasma Shaukat
Journal: JAMA Network Open (2024)

Daniel S. Reuland, MD, MPH; Meghan C. O'Leary, PhD, MA; Seth D. Crockett, MD, MPH; Deeonna E. Farr, DrPH, MPH; Renée M. Ferrari, PhD, MPH; Teri L. Malo, PhD, MPH; Alexis A. Moore, MPH; Connor M. Randolph, BA; Shana Ratner, MD; Lindsay R. Stradtman, MPH; Christina Stylianou, BS; Kevin Su, MPH; Xianming Tan, PhD; Van Tang, MS; Stephanie B. Wheeler, PhD, MPH; Alison T. Brenner, PhD
Is Greater Access to Youth Sport the Key to Eliminating Physical Activity Disparities?
Authors: Phil T. Veliz, William V. Massey, Nicole Zarrett
Journal: JAMA Network Open (2024)

Kosuke Tamura, PhD; Marie F. Martinez, MSPH; Yangyang Deng, PhD; Jessie Heneghan, MCP; Colleen Weatherwax, MS; Kavya Velmurugan, BS; Kevin L. Chin, MPH; Breanna Rogers, BS; Mohammad Moniruzzaman, PhD; Meredith Whitley, PhD; Sarah M. Bartsch, MPH; Kelly J. O'Shea, BSFS; Alexis Dibbs, BS; Sheryl Scannell, MS; Bruce Y. Lee, MD, MBA
As-Needed Blood Pressure Medication and Adverse Outcomes in VA Hospitals
Authors: Muna Thalji Canales, Seonkyeong Yang, Anders Westanmo, Xinping Wang, Dexter Hadley, Areef Ishani, Rajesh Mohandas, Ronald Shorr, Weihsuan Lo-Ciganic
Journal: JAMA Internal Medicine (2024)

Asymptomatic blood pressure (BP) elevations in the hospital are commonly treated with as-needed BP medications, including recurring as-needed and 1-time administration. Veterans represent a population at risk of ischemic events from rapid lowering of BP, but the impact of as-needed BP medication use in this population is unknown.
Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease
Authors: Yilun Wang, Nicola Dalbeth, Robert Terkeltaub, Yuqing Zhang, Xiaoxiao Li, Chao Zeng, Guanghua Lei, Jie Wei
Journal: JAMA Internal Medicine (2024)

Importance Clinicians often approach urate-lowering therapy (ULT) cautiously in patients with gout and impaired kidney function because they are concerned about the risk of progression to severe or end-stage kidney disease. However, evidence from randomized clinical trials of this association remains inconclusive. Objective To evaluate the association between achieving target serum urate level with ULT and progression of chronic kidney disease (CKD) to severe or end-stage in patients with gout and impaired kidney function. Design, Setting, and Participants This was a cohort study using the target trial emulation approach using data from a general practice database (IQVIA Medical Research Database) for 2000 to 2023. Eligible patients were 40 to 89 years old and had gout and CKD stage 3. Data analyses were performed from November 2023 to September 2024. Exposures Lowering serum urate level to target level (&amp;amp;lt;6 mg/dL) using ULT. Main Outcomes and Measures Severe or end-stage kidney disease, determined by an estimated glomerular filtration rate of less than 30 mL/min/1.73 m 2 on at least 2 occasions more than 90 days apart within 1 year, or at least 1 Read code (per the Refined Etiology, Anatomical Site, and Diagnosis classification) for CKD stages 4 or 5, hemodialysis, peritoneal dialysis, or kidney transplant. The prespecified noninferiority margin of the hazard ratio (HR) was set at 1.2, comparing those who achieved the target serum urate level with those who did not. Results Among the 14 792 participants (mean [SD] age, 73.1 [9.5] years; 9215 men [62.3%] and 5577 women [37.7%]) with gout and with CKD stage 3, the 5-year risk of severe or end-stage kidney disease was 10.32% for those who achieved the target serum urate level and 12.73% for those who did not. Compared with those not achieving the target level, the adjusted 5-year risk difference and HR of severe or end-stage kidney disease for patients achieving the target serum urate level was −2.41% (95% CI, −4.61% to −0.21%) and 0.89 (95% CI, 0.80 to 0.98), respectively. Conclusions and Relevance The findings of this cohort study indicate that in patients with gout and CKD stage 3, lowering serum urate level to less than 6 mg/dL vs 6 mg/dL or greater using ULT was not associated with an increased risk of severe or end-stage kidney disease. These findings support optimizing ULT to achieve target serum urate levels when treating patients with gout and impaired kidney function.
Lifestyle Modification for Obesity Management—A Cornerstone and Not a Roadblock
Authors: Ilana Richman, Eve Rittenberg
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Assessment of Home-based Monitoring in Adults with Chronic Lung Disease. An Official American Thoracic Society Research Statement
Authors: Yet H Khor, Vitalii Poberezhets, Russell G. Buhr, James D. Chalmers, Hayoung Choi, Vincent S. Fan, Maureen George, Anne E Holland, Hilary Pinnock, Christopher J Ryerson, Rachel Alder, Kerri I Aronson, Teresa Barnes, Roberto Benzo, Surinder S Birring, Jeanette Boyd, Barbara Crossley, Ron Flewett, Michael Freedman, Toni Gibson, Linzy Houchen-Wolloff, Uma M. Krishnaswamy, John Linnell, Fernando J. Martinez, Catharina C. Moor, Hilarry Orr, Andrea A. Pappalardo, Isabel Saraiva, Karin Wadell, Henrik Watz, Marlies S. Wijsenbeek, Jerry A Krishnan
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Background: There is increasing interest in the use of home-based monitoring in people with chronic lung diseases to improve access to care, support patient self-management, and facilitate the collection of information for clinical care and research. However, integration of home-based monitoring into clinical and research settings requires careful consideration of test performance and other attributes. There is no published guidance from professional respiratory societies to advance the science of home-based monitoring for chronic lung disease. Methods: An international multidisciplinary panel of 32 clinicians, researchers, patients, and caregivers developed a multidimensional framework for the evaluation of home-based monitoring in chronic lung disease developed through consensus using a modified Delphi survey. We also present an example of how the framework could be used to evaluate home-based monitoring using spirometry and pulse oximetry in adults with asthma, bronchiectasis/cystic fibrosis, chronic obstructive pulmonary disease, and interstitial lung disease. Results: The PANACEA framework includes seven domains (test Performance, disease mANAgement, Cost, patient Experience, clinician Experience, researcher Experience, and Access) to assess the degree to which home-based monitoring assessments meet the conditions for clinical and research use in chronic lung disease. Knowledge gaps and recommendations for future research of home spirometry and pulse oximetry in asthma, bronchiectasis/cystic fibrosis, chronic obstructive pulmonary disease, and interstitial lung disease were identified. Conclusions: The development of the PANACEA framework allows standardized evaluation of home-based monitoring in chronic lung diseases to support clinical application and future research.
Contraception Choice Beyond Efficacy—Reply
Authors: Shaketha A. Gray, Lindsay A. Thompson
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Evaluating the association between the introduction of mandatory calorie labelling and energy consumed using observational data from the out-of-home food sector in England
Authors: Megan Polden, Andrew Jones, Michael Essman, Jean Adams, Tom R. P. Bishop, Thomas Burgoine, Stephen J. Sharp, Martin White, Richard Smith, Aisling Donohue, Rozemarijn Witkam, I. Gusti Ngurah Edi Putra, Jane Brealey, Eric Robinson
Journal: Nature Human Behaviour (2024)

In April 2022, mandatory kilocalorie (kcal) labelling in the out-of-home food sector was introduced as a policy to reduce obesity in England. Here we examined whether the implementation of this policy was associated with a consumer behaviour change. Large out-of-home food sector outlets subject to kcal labelling legislation were visited pre- and post-implementation, and customer exit surveys were conducted with 6,578 customers from 330 outlets. Kcals purchased and consumed, knowledge of purchased kcals and reported noticing and use of kcal labelling were examined. The results suggested that the introduction of the mandatory kcal labelling policy in England was not associated with a significant decrease in self-reported kcals purchased (B = 11.31, P = 0.564, 95% confidence interval (CI) -27.15 to 49.77) or consumed (B = 18.51, P = 0.279, 95% CI -15.01 to 38 52.03). Post-implementation, participants underestimated the energy content of their purchased meal less (B = 61.21, P = 0.002, 95% CI 21.57 to 100.86) and were more likely to report noticing (odds ratio 2.25, P < 0.001, 95% CI 1.84 to 2.73) and using (odds ratio 2.15, P < 0.001, 95% CI 1.62 to 2.85) kcal labelling, which may have wider public health implications.
Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US
Authors: Olivier J. Wouters, Matthew Vogel, William B. Feldman, Reed F. Beall, Aaron S. Kesselheim, S. Sean Tu
Journal: JAMA (2024)

Importance Biologics approved by the US Food and Drug Administration (FDA) receive 12 years of guaranteed protection from biosimilar competition compared with 5 years of protection from generic competition for new small-molecule drugs. Under the 2022 Inflation Reduction Act, biologics are exempt from selection for Medicare price negotiation for 11 years compared with 7 years for small-molecule drugs. Congress codified these differing legal protections on the premise that biologics require more time and resources to develop and have weaker patent protection, necessitating additional protections for manufacturers to recoup their development costs and generate adequate returns on investment. Objective To review empirical evidence from the US experience with biologics to analyze the assumptions underlying longer periods of market exclusivity and protection from price negotiation compared with small-molecule drugs. Evidence Review Recent data on development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment costs of biologics vs small-molecule drugs were analyzed. Findings The FDA approved 599 new therapeutic agents from 2009-2023, of which 159 (27%) were biologics and 440 (73%) were small-molecule drugs. Median development times were 12.6 years (IQR, 10.6-15.3 years) for biologics vs 12.7 years (IQR, 10.2-15.5 years) for small-molecule drugs ( P = .76). Biologics had higher clinical trial success rates at every phase of development. Median development costs were estimated to be $3.0 billion (IQR, $1.3 billion-$5.5 billion) for biologics and $2.1 billion (IQR, $1.3 billion-$3.7 billion) for small-molecule drugs ( P = .39). Biologics were protected by a median of 14 patents (IQR, 5-24 patents) compared with 3 patents (IQR, 2-5 patents) for small-molecule drugs ( P &amp;amp;lt; .001). The median time to biosimilar competition was 20.3 years (IQR, 16.9-21.7 years) compared with 12.6 years (IQR, 12.5-13.5 years) for small-molecule drugs. Biologics achieved higher median peak revenues ($1.1 billion in year 13; IQR, $0.5 billion-$2.9 billion) than small-molecule drugs ($0.5 billion in year 8; IQR, $0.1 billion-$1.2 billion; P = .01) and had higher median revenues in each year following FDA approval. The median annual cost of treatment was $92 000 (IQR, $31 000-$357 000) for biologics and $33 000 (IQR, $4000-$177 000) for small-molecule drugs ( P = .005). Conclusions and Relevance There is little evidence to support biologics having longer periods of market exclusivity or protection from negotiation. As a result of differential treatment, US law appears to overly reward the development of biologics relative to small-molecule drugs.
Association of Severe Maternal Morbidity With Subsequent Birth
Authors: Eleni Tsamantioti, Anna Sandström, Charlotte Lindblad Wollmann, Jonathan M. Snowden, Neda Razaz
Journal: JAMA (2024)

Importance Women who experience severe maternal morbidity (SMM) might have lasting health issues, and the association of SMM with the probability of future reproductive intentions is unknown. Objective To examine the association between SMM in a first birth and the probability of a subsequent birth. Design, Setting, and Participants Retrospective, population-based cohort study conducted among 1 046 974 women in Sweden who had their first birth between 1999 and 2021. Exposure Overall SMM and SMM subtypes were identified among all deliveries at 22 weeks of gestation or later (including complications within 42 days of delivery) from the Swedish Medical Birth Register and National Patient Register. Main Outcomes and Measures All women with a recorded first delivery were followed up from 43 days postpartum until the first day of the last menstrual period of the second pregnancy that resulted in a birth (stillbirth or live birth) or until death, emigration, or end of follow-up on December 31, 2021. Multivariable Cox proportional hazards regression was used to estimate associations between SMM and time to subsequent birth with adjusted hazard ratios (aHRs). Sibling analysis was performed to evaluate potential genetic and familial confounding. Results A total of 36 790 women (3.5%) experienced an SMM condition in their first birth. Women with any SMM had a lower incidence rate of subsequent birth compared with those without SMM in their first delivery (136.6 vs 182.4 per 1000 person-years), with an aHR of 0.88 (95% CI, 0.87-0.89). The probability of subsequent birth was substantially lower among women with severe uterine rupture (aHR, 0.48; 95% CI, 0.27-0.85), cardiac complications (aHR, 0.49; 95% CI, 0.41-0.58), cerebrovascular accident (aHR, 0.60; 95% CI, 0.50-0.73), and severe mental health conditions (aHR, 0.48; 95% CI, 0.44-0.53) in their first birth. The associations were not influenced by familial confounding as indicated by sibling analyses. Conclusions and Relevance Our findings suggest that women who experience SMM in their first birth are less likely to have a subsequent birth. Adequate reproductive counseling and enhancing antenatal care are crucial for women with a history of SMM.
Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors
Authors: Derrick L. Tao, Mirella Nardo, Cheuk Hong Leung, Heather Y. Lin, Lei Kang, Hung Le, Ecaterina E. Dumbrava, David S. Hong
Journal: JAMA Network Open (2024)

This cohort study investigates the association of obesity with adoptive cell therapy outcomes in patients with solid tumors.
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response
Authors: Jean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, Diego Teyssonneau, Lola-Jade Palmieri, Emma Clot, Sophie Cousin, Guilhem Roubaud, Mathilde Cabart, Laura Leroy, Coriolan Lebreton, Christophe Rey, Oren Lara, Ophélie Odin, Maxime Brunet, Lucile Vanhersecke, Ezogelin Oflazoglu Gruyters, Ikbel Achour, Leila Belcaid, Sylvestre Le Moulec, Thomas Grellety, Alban Bessede, Antoine Italiano
Journal: Cell Reports Medicine (2024)
Pelvic Desmoplastic Small Round Cell Tumor on 18F-PSMA PET/CT
Authors: Yuan Wang, Xiaohui Ding, Ruimin Wang, Yachao Liu
Journal: Clinical Nuclear Medicine (2024)

Abstract Desmoplastic small round cell tumor (DSRCT) as a subtype of sarcoma is rare and aggressive. We present the case of a 23-year-old man with a histologically confirmed DSRCT who underwent 18 F-PSMA PET/CT before prostate biopsy and surgical resection of the tumor. It is well known that PSMA PET has a high accuracy for detecting clinically significant prostate adenocarcinoma and is useful in guiding prostate biopsy. This case signifies DSRCT can also exhibit intermediate PSMA expression on 18 F-PSMA PET/CT.
Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation
Authors: Gal Tsaban, Eunjung Lee, Samual Wopperer, Muhannad Abbasi, Hee Tae Yu, Garvan C Kane, Francisco Lopez-Jimenez, Sorin V Pislaru, Vuyisile T Nkomo, Abhishek J Deshmukh, Samuel J Asirvatham, Peter A Noseworthy, Paul A Friedman, Zachi Attia, Jae K Oh
Journal: Journal of the American College of Cardiology (2024)
Childhood, adolescent and young adulthood cancer risk in <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant carriers
Authors: Shuai Li, Laura Madanat-Harjuoja, Goska Leslie, Daniel R Barnes, Manjeet K Bolla, Joe Dennis, Michael T Parsons, Paraskevi Apostolou, Norbert Arnold, Kristin Bosse, Antonis C Antoniou on behalf of EMBRACE Collaborators, Jackie Cook, Christoph Engel, D Gareth Evans, Florentia Fostira, Megan N Frone, Andrea Gehrig, Mark H Greene, Karl Hackmann, Eric Hahnen, Nadia Harbeck, Jan Hauke, Julia Hentschel, Judit Horvath, Louise Izatt, Marion Kiechle, Irene Konstantopoulou, Fiona Lalloo, Joanne Ngeow Yuen Yie, Dieter Niederacher, Julia Ritter, Marta Santamariña, Rita K Schmutzler, Claire Searle, Christian Sutter, Marc Tischkowitz, Vishakha Tripathi, Ana Vega, Hannah Wallaschek, Shan Wang-Gohrke, Barbara Wappenschmidt, Bernhard H F Weber, Drakoulis Yannoukakos, Emily Zhao, Douglas F Easton, Antonis C Antoniou, Georgia Chenevix-Trench, Timothy R Rebbeck, Lisa R Diller
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Whether carriers of BRCA1 or BRCA2 (BRCA1/2) pathogenic variants (PVs) have increased risks of childhood, adolescent, and young adult (CAYA) cancers is controversial. We aimed to evaluate this risk and to inform clinical care of young BRCA1/2 PV carriers and genetic testing for CAYA cancer patients. Methods Using data from 47,117 individuals from 3,086 BRCA1/2 families, we conducted pedigree analysis to estimate relative risks (RRs) for cancers diagnosed before age 30. Results Our data included 274 cancers diagnosed before age 30: 139 breast cancers, 10 ovarian cancers, and 125 non-breast non-ovarian cancers. Associations for breast cancer in young adulthood (20-29 years) were found with RRs of 11.4 (95% CI: 5.5, 23.7) and 5.2 (95% CI: 1.6, 17.7) for BRCA1 and BRCA2 PV carriers, respectively. No association was found for any other investigated CAYA cancer, nor for all non-breast non-ovarian cancers combined: the RRs were 0.4 (95% CI: 0.1, 1.4) and 1.4 (95% CI: 0.7, 3.0) in BRCA1 or BRCA2 PV carriers, respectively. Conclusion We found no evidence that BRCA1/2 PV carriers have an increased CAYA cancer risk aside from breast cancer in women in their 20’s. Our results, along with a critical evaluation of previous germline sequencing studies, suggest that the childhood and adolescent cancer risk conferred by BRCA1/2 PV would be low (ie, RR &amp;lt; 2) if it existed. Our findings do not support PV testing for offspring of BRCA1/2 PV carriers at ages &amp;lt;18 years, nor for conducting BRCA1/2 PV testing for childhood and adolescent cancer patients.